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Abstract
There is currently no consensus on approaches to defining asthma or assessing asthma outcomes
using electronic health record (EHR)-derived data. We explored these approaches in the recent
literature, and examined the clarity of reporting.
We systematically searched for asthma-related articles published between 1-1-2014 and 31-12-
2015, extracted the algorithms used to identify asthma patients and assess severity, control and
exacerbations, and examined how the validity of these outcomes was justified.
From 113 eligible articles, we found significant heterogeneity in the algorithms used to define
asthma (n=66 different algorithms), severity (n=18), control (n=9), and exacerbations (n=24).
For the majority of algorithms (n=106), validity was not justified. In the remaining cases,
approaches ranged from using algorithms validated in the same databases, to using non-validated
algorithms that were based on clinical judgement or clinical guidelines. The implementation of
these algorithms was sub-optimally described overall.
Although EHR-derived data are now widely used to study asthma, the approaches being used
are significantly varied and are often underdescribed, rendering it difficult to assess the validity
of studies and compare their findings. Given the substantial growth in this body of literature, it
is crucial that scientific consensus is reached on the underlying definitions and algorithms.
Keywords: Algorithms; asthma; electronic health records; quality of reporting; reproducibility.
Take home message (117 characters for social media)
Inconsistent/underdescribed #asthma case definitions are common in research, limiting #repro-
ducibility/#comparability
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Introduction
Asthma is in clinical practice a diagnosis based on the patient history, examination and objective
tests [1]. It is however increasingly considered to represent a heterogeneous group of disorders
with different phenotypes and endotypes [2]. The clinical definitions of asthma and its key
outcomes, including disease severity, control, and attacks/exacerbations have been the subject of
vigorous debate [3–8].
Particular challenges arise in the context of epidemiologic studies where validated operational
definitions are needed [9, 10]. These studies are, increasingly, being undertaken using electronic
health record (EHR)-derived data, which adds a further layer of complexity as the use of valid
and reliable approaches is essential in order to ensure the reproducibility of research findings
[11].
In order to assess current approaches, we systematically interrogated the recent EHR-based
asthma literature. Our specific objectives were to: i) describe the different methods of defining
asthma and assessing disease severity, control and exacerbations in EHR-based studies; ii)
investigate whether authors reported on the validity of those methods; and iii) assess their
reporting practices.
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Methods
We conducted a systematic scoping review based on Arksey and O’Malley’s five-stage frame-
work, including identifying the research question, identifying relevant studies, study selection,
data charting and collating, summarising and reporting the results [12]. The research questions
were: (1) How were asthma and its key outcomes defined using EHR data in the recent literature?
(2) How did authors report on the validity of their EHR-based algorithms? (3) How clearly were
the EHR-related methods reported?
Eligibility criteria and search strategy
We searched PubMed using a broad query (Table E1) to retrieve asthma studies that used EHR-
derived data and were published between January 1, 2014 and December 31, 2015. The search
query was iteratively improved by adding many variations and equivalents of the keywords
“EHR” and “routinely collected data” as well as named data sources found in the literature. Only
articles written in English were included.
Study selection
We excluded non-relevant articles by reviewing titles and abstracts, referring to the full-text
when needed. We included only articles where asthma was a main finding. For the purpose of
this review, we limited the concept of EHR-derived data to coded, objective, individual-level
data that were generated as a by-product of routine health care.
Data extraction and synthesis
From each of the eligible articles, we extracted and summarised information from the full text
and online supplements, including basic bibliography, setting (country) and design; names
and types of EHR-derived data sources used; algorithms to identify asthma patients, assess
disease severity, control, exacerbation; and how authors reported on algorithm validity. In
this context, we referred to ‘validation’ as any attempt to assess the algorithm’s concurrent or
construct validity. We used the RECORD Statement’s 13-items checklist to assess the clarity
of reporting of other EHR-related aspects such as clinical code lists used in the algorithms,
and the implications of using EHR data in asthma research. The RECORD Statement is a
recently introduced extension to the STROBE Statement which helps improve the reporting of
observational studies conducted using routinely collected data [13]. Table E2 describes the data
extraction and charting tool. Article screening and data extraction were performed independently
by two authors (MAS and EV) with a third author arbitrating (GAD).
Role of the funding sources
The funding sources had no role in study design; in the collection, analysis, and interpretation of
data; in the writing of the report; or in the decision to submit the paper for publication.
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Results
We included 113 articles in the review. Figure 1 shows the study selection process. Most studies
were conducted in the United States (US), Taiwan, and Canada (Table E3), and employed
longitudinal designs (Table E4). The most commonly used data types were health insurance
claims followed by medical record repositories and dispensing databases (Table E5).
307 articles identified
through database searching
307 articles screened
155 full-text articles
assessed for eligibility
113 studies included in
qualitative synthesis
152 records excluded
42 full-text articles excluded
Figure 1: Flowchart for study selection in this scoping review.
Defining asthma
We identified 66 different algorithms to define asthma under seven diagnostic labels (Table E6).
‘Persistent asthma’ was defined over 12 and 24 months using the US Healthcare Effectiveness
Data and Information Set (HEDIS) criteria [14], which involved assessing for any of the
following asthma-related events: (1) emergency department (ED) visit, (2) hospitalisation,
(3) outpatient visit and two asthma prescriptions, or (4) four asthma prescriptions [15–18];
by HEDIS criteria except “four asthma prescriptions” [19]; and by any asthma encounter
(hospitalisation or ED visit) or using oral corticosteroids (OCS) for three or more days [20].
‘Current asthma’ was defined by any asthma encounter in the last three years [21].
‘Current general practitioner (GP)-reported and diagnosed asthma’ was defined as any asthma
encounter in the last 12 months, and ‘current GP-reported, diagnosed and treated asthma’ as
the same plus any asthma prescription in the same period [22].
Patients with treated asthma were otherwise required to have at least three dispensing events of
asthma treatments in three different quarters of the year [23].
‘Acute asthma’ was defined using any asthma diagnosis codes in ED or inpatient data [24].
In the remaining studies, the label ‘asthma’ was defined using various algorithms, some of
which were similar to those of the aforementioned more specific labels.
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The intervals over which asthma diagnostic/management and prescription codes where queried
were specified in 31 and 8 studies, respectively. The positions of diagnostic codes in the
encounter (i.e. primary or secondary) were specified in 37 studies.
We identified five approaches in these algorithms: requiring diagnostic/management events,
prescription events, or both (Table E7). In addition, to exclude likely non-asthma patients, some
studies applied additional non-asthma criteria to restrict the study population based on age
(Table E8) and/or comorbidities (Table E9).
Assessing asthma severity
Eighteen studies used 20 different algorithms to assess asthma severity (Table E10), as binary
(i.e. severe vs. non-severe asthma) [15, 23, 25–38] or ordinal variables (mild, moderate,
and severe asthma [39]; or low, moderate, and high-risk asthma [40]). The algorithms were
based on one or more of the following asthma-related variables: number and/or dosage of
prescriptions—namely SABA, inhaled corticosteroids (ICS), OCS, and leukotriene receptor
antagonist (LTRA)—and number of hospitalisations, ED and outpatient visits. Almost all
algorithms (17) used prescriptions (either alone or with other variables), while one algorithm
was based only on hospitalisations and ED visits [36]. The intervals over which asthma severity
was assessed were three [29], six [38], 12 [15, 23, 28, 30–32, 34, 36, 37, 39, 40], 24 months [33,
35], or unclear [26, 27].
Assessing asthma control
Nine studies assessed asthma control using 11 algorithms, in 9 of which the interval was
12 months, in one 1-3 months, and in the remaining study this was unclear (Table E12).
Uncontrolled asthma was defined by a minimum number/dose of SABA prescriptions [30,
31, 39, 41, 42]; any or short-course OCS prescriptions [30, 31, 41–44]; any hospitalisation or ED
visit with either diagnosis of asthma [27, 30, 31, 41–43, 45] or — in already diagnosed asthma
patients — diagnosis of status asthmaticus, pneumonia, dyspnoea, or respiratory insufficiency
[30]; unscheduled outpatient visits for asthma or lower respiratory tract infections (LRTI) [31];
and GP consultations for LRTI requiring antibiotics in asthma patients [31]. Asthma impairment
was defined based on the required SABA use, namely an average of more than two salbutamol
puffs per day [31]. One study assessed asthma control based on number of OCS and SABA
prescriptions per year (without giving any further details about the actual algorithm) [41].
Defining exacerbations
Twenty-four studies defined exacerbations using EHR-derived data (Table E11), as a dichoto-
mous variable (absent vs. present) [16, 17, 23, 27, 30–32, 35, 37–39, 42–44, 46–54], or stratified
into absent, moderate and severe [55]. Oral corticosteroid prescriptions were used as a marker for
exacerbations in 17 studies, either alone [23, 30, 31, 35, 39, 42, 47, 48, 53] or with a concurrent
asthma encounter (e.g., a GP, outpatient, or ED visit, or hospitalisation within five or seven days)
[16, 17, 32, 37, 38, 46, 52, 54]. In one study, exacerbations were defined by a minimum of six
short-acting beta-2 agonist (SABA) prescriptions per year [47]. Other definitions included an
outpatient code of ‘asthma exacerbation’ [52], asthma hospitalisation [23, 30, 32, 35, 37, 39, 43,
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Table 1: Practices of reporting or justifying the validity of algorithms to define and assess asthma
using EHR-derived data.
Algorithm validity was justified by Number of algorithms
Identifying
asthma
pa-
tients
Assessing
sever-
ity
Assessing
control
Defining
exacer-
bation
Total
per
cate-
gory
Validation of the same algorithm in the same database 14 1 1 1 17
Validation of the same algorithm in different database(s) 2 6 3 2 13
Validation of other diseases’ algorithms in the same database 2 0 0 0 2
Validation of other diseases’ algorithms in different database(s) 1 0 0 0 1
Being consistent with similar studies in the same database 1 0 1 0 2
Being consistent with similar studies in different database(s) 1 0 0 1 2
Validation or concordance analysis in the same study 4 0 0 0 4
Being based on nationally developed algorithms 3 0 0 2 5
Relying on the validity of database coding 5 0 0 0 5
Being based on clinical guidelines 0 3 0 0 3
Not justified 76 8 4 18 106
44, 46, 48, 50, 51, 53–55], asthma ED visit [16, 30–32, 35, 37, 38, 43, 44, 46, 48, 51–54], or
hospitalisation with diagnosis of status asthmaticus, or — in already diagnosed asthma patients
— diagnosis of pneumonia, dyspnoea, or respiratory insufficiency [30].
Clarity of reporting
Overall, the reporting of methodological aspects of using EHR-derived data was suboptimal.
The majority of studies presented no information on the algorithms’ validity. Among studies
that reported on the validity, we identified 10 practices of reporting or justifying on the validity
of algorithms (Table 1): (1) performing validation or concordance analysis in the same study
against other measures based on different data sources (e.g., medical record review or patient-
reported measures); (2) referring to previous validation of similar algorithms in the same or
(3) different databases; (4) referring to previous validation of similar algorithms for different
diseases in the same or (5) different database (6); using algorithms ‘consistent’ with previous
studies in the same or (7) different databases; (8) using nationally developed algorithms; (9)
using algorithms based on clinical guidelines; (10) and relying on previous validation of the
database content. Some studies did not provide clear algorithms for asthma severity or control,
but only referred to their components [23, 35, 37, 38, 41].
Of the 113 reviewed studies, 40 studies used record-linkage, of which 17 mentioned it in the
abstract, and 28 provided at least some explanation in the full text. The geographical region,
time frame of data, and types or names of the data sources were mentioned in 83, 91, and 104
abstracts, respectively. Eighty-three studies reported their extent of access to the data sources.
The intervals over which the algorithms were applied were often not reported. One hundred and
eleven studies touched on the implications of using EHR data to study asthma. Of these, 64 and
63 studies discussed the risk of misclassification bias and unmeasured confounding, respectively.
Six studies acknowledged the possible changes over time in data quality and coding practices
and the entailing changes in case definition eligibility and accuracy. Five studies explained their
data cleansing procedures. Finally, no study shared the programming codes of data preparation
and analysis.
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Discussion
Statement of principal findings
This systematic analysis of the contemporaneous asthma literature has found evidence of
considerable international activity in using EHR-derived data to study a variety of asthma
populations and outcomes. Importantly, we also found wide variations in the approaches used
with limited attention being paid to the validity of the underlying algorithms used and suboptimal
reporting of studies. This poses a major challenge to the interpretation and reproducibility of
this important, emerging body of research inquiry.
Strengths and limitations
To our knowledge, this is the first systematic exercise to investigate the quality of reporting on
EHR-based studies, especially the validity of measures, in the context of asthma. In undertaking
this work, we used robust approaches which involved two people independently selecting
studies and undertaking data extraction. The findings may also apply to other chronic diseases.
This review had no geographic limits, but it was confined to assessing the recent literature.
Examining the most recent asthma literature is most likely to provide meaningful insights on
current practices. A limitation is that we did not systematically check whether the references
provided to support the claimed validity of algorithms in question actually provided sufficient
evidence of validity. For example, differences might exist between the algorithms used in a
given study and those previously validated.
Interpretation in the light of previous studies
Although EHR-derived data are convenient resources for research, they are originally collected
for other purposes, and usually suffer from missing or incorrect data and potential biases [56–58].
In addition, EHR systems usually fail to capture complete and accurate clinical information at
the point of care due to design limitations and inefficient use of these systems by clinicians to
document clinical data [59, 60].
These issues impose challenges on their use to assess a complex and heterogeneous condition
such as asthma. For example, asthma diagnosis codes, which are commonly used solely for
patient identification, may be recorded after a trial or wrong diagnosis, and do not capture
undiagnosed patients [61]. In addition, many EHR-derived databases often lack important
variables, such as lung function, indication of dispensed medications, adherence to treatment,
and lifestyle, which are vital for identifying and assessing asthma patients. These challenges are
however not insurmountable. In this review, we found several techniques intended to improve
algorithm accuracy such as age limitation, comorbidity exclusion, and diagnosis position
restriction.
Ideally, algorithms should be validated in the databases in which they are used. However, this
was often not the case. Instead, using algorithms with only reasonable face validity based
on clinical guidelines or clinical judgement is a very common practice in EHR-based studies
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[62, 63]. These approaches assume that clinical codes in the database accurately represent the
patient’s actual health care events [62].
Under-reporting on implementation details and methods’ validity compromises transparency
and reproducibility, a crucial issue in medical research. It has been previously found that in
EHR-based studies, full lists of clinical codes were often not reported [64]. A recent, large-scale
reproducibility exercise identified similar challenges due to suboptimal reporting of EHR-based
studies, particularly sharing code lists and algorithms [65].
The significant methodological heterogeneity we found in EHR-based asthma assessment
algorithms reflects, in addition to the content differences between the databases used, the lack
of consensus on the clinical definitions in the first place despite continuous standardisation
efforts [5, 6, 66, 67]. The focus of our work was to examine asthma definitions and their validity
specifically in the context of EHR, but this highlights the fundamental need to reach consensus
on clinical asthma definitions and the appropriate validation of asthma diagnosis. For example,
there is still an active debate on whether lung function is essential to establish asthma diagnosis
[7, 8]. A recent study also found significant variation in algorithms to assess asthma severity
from health insurance data [68]. Unjustified inter-study variation in the operational definitions
of the same clinical concepts creates challenges for comparability, meta-analysis and evidence
synthesis. These issues have been raised for asthma [69] and other allergic conditions such as
peanut allergy [70, 71] and anaphylaxis [72], where wide variations in findings were potentially
attributed to inconsistent case definitions.
Implications for policy, practice and research
This review sheds light on the opportunities offered by the increasingly ubiquitous EHRs, but also
highlights considerable heterogeneity and suboptimal reporting of EHR-based asthma assessment
algorithms and the implications of these practices on comparability and reproducibility of studies.
Developing reliable algorithms to assess asthma outcomes using EHR data is a non-trivial
challenge. In addition, standardising such algorithms across different populations may be
impractical since databases differ in content, validity may not hold across different populations,
and no best practice currently exists [68]. Similar challenges arise when comparing asthma
epidemiology between multiple populations [73]. These methodologic issues, in addition to
suboptimal reporting, should be considered when interpreting and synthesising evidence from
geographically dispersed studies.
With the accelerating availability of EHR-derived data and their use to study asthma, we believe
that consideration needs to be given to convening an international task force to work on the
harmonisation of those algorithms under uniform and consistent clinical labels, while considering
the differences between populations and databases. In addition, validation of these algorithms in
the respective populations should be given a high priority. Furthermore, to allow more accurate
assessment of asthma from EHR data, efforts are needed to improve the capture and coding of
asthma-related data at the point of care [74] which requires more efficient EHR systems [59,
60]. In addition, emerging data sources such as patient-generated data and wearables need to
be harnessed [75]. Finally, to improve the clarity of reporting on EHR-related methodological
aspects, we strongly advocate the adoption of the RECORD Statement as an extension of the
STROBE Statement by both authors and journal editors [13]. Optimal reporting should include
complete code lists, detailed algorithms and validity assessment. Implications of using EHR-
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derived data to study a complex condition such as asthma should be clearly communicated to
enable judgement of internal and external validity.
In summary, we have found that there is considerable international interest in exploiting EHR-
derived data to study asthma, but that there are considerable variations in the approaches used.
These variations are compounded by sub-optimal reporting of methods, which makes it difficult
to assess the reproducibility of research. Given the substantial investments taking place in EHRs
globally, this body of work is likely to grow significantly in the coming years. It is therefore
important that the asthma-interested research community works to place it on a solid footing in
order to ensure the quality and reproducibility of this work.
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Table E1: Search query (adapted from [E1])
Search
ID
Query Number of
matching
articles
#1 Search ("humans"[mh] AND English[lang] AND ("2014/01/01"[PDat] : "2015/12/31"[PDat]) AND "loattrfull text"[sb] AND ( Asthma[mh] OR
"Anti-Asthmatic Agents"[mh] ) AND ( Asthma[tiab] OR Asthmatic[tiab] OR Asthmatics[tiab] ) NOT "Comment" [pt] NOT "Editorial"[pt] NOT
"Letter" [pt] NOT "review"[pt] NOT "Meta-Analysis" [pt] NOT "clinical trial"[pt] NOT "Randomized Controlled Trial" [pt] NOT "Clinical Trial,
Phase I" [pt] NOT "Clinical Trial, Phase II" [pt] NOT "Clinical Trial, Phase III" [pt] NOT "Clinical Trial, Phase IV" [pt] NOT "Controlled Clinical
Trial" [pt] NOT "Clinical Trials as Topic" [Mesh] NOT "double-blind" [All] NOT "placebo-controlled" [All] NOT "case reports" [pt] NOT "pilot study"
[All] NOT "pilot projects" [Mesh] NOT "Prospective Studies" [Mesh])
3164
#2 "GPRD" OR "CPRD" OR "Clinical Practice Research Datalink" OR "General Practice Research Database" OR "SAIL databank" OR "Secure
Anonymised Information Linkage Databank" OR "Hospital Episode Statistics" OR ("HES" AND "England") OR "Mediplus" OR "DIN-LINK" OR
"QResearch" OR "RiRL" OR "Research in Real Life" OR "Paediatric Intensive Care Audit Network" OR "PICANet" OR "Scottish Drug Misuse
Database" OR "Prescribing Information System" OR "Maternity and Neonatal Linked Database" OR "Office for National Statistics" OR ("ONS" AND
("UK" OR "United Kingdom")) OR "Primary Care Mortality Database" OR "PCMD" OR "Emergency department Data Set" OR "National
Community Child Health Database" OR "Outpatient Dataset" OR "Patient Episode Database for Wales" OR "PEDW" OR "Primary Care dataset" OR
OR "Primary Care GP dataset" OR "Maternity and Neonatal Linked Database" OR "Prescribing Information System" OR "Scottish Birth Record" OR
"Scottish Drug Misuse Database" OR "Scottish Morbidity Records" OR "Scottish morbidity" OR "SMR01" OR "SMR00" OR "Outpatient Attendance
dataset" OR "SMR01" OR "General / Acute Inpatient and Day Case dataset" OR "Department of Health Victoria Australia" OR "Clalit Health Service
computerized databases" OR "National Health Insurance Research Database" OR "NHIRD" OR "Portuguese Anti-Doping authority database" OR
"Children’s Hospital Srebrnjak Database" OR "CHSD" OR "Practice Team Information" OR "Norwegian Prescription Database" OR "NorPD" OR
"National Health Insurance Claims Database" OR "Longitudinal Health Insurance Database" OR "LHID" OR "Medical Birth Registry" OR "Medical
Birth Register" OR "Statistics Norway" OR "National Insurance Scheme" OR "Medco Health Solutions administrative database" OR "Discharge
Abstract Database") OR "Ontario Asthma Database" OR "Ontario COPD Database" OR "Ontario Hypertension Database" OR "Ontario Diabetes
Database" OR "Surveillance, Epidemiology and End Results" OR "SEER" OR "National Board of Health and Welfare and Statistics" OR "Prescribed
Drug Register" OR "National Patient Registry" OR "Optimum Patient Care Research Database" OR "OPCRD" OR "Hospital Discharge Register" OR
"Cause of Death Register" OR "Register of Population and Population Changes" OR "British Thoracic Society Difficult Asthma Registry" OR
"InterAction Database" OR "IADB" OR "Total Population Register" OR "Multi-Generation Register" OR "Prescribed Drug Register" OR "PDR" OR
"National Patient Register" OR "NPR" OR "Statistics Denmark" OR "Odense Pharmaco-Epidemiological Database" OR "Register of Medicinal
Product Statistics" OR "RMPS" OR "Register of Medical Product Statistics" OR "RMPS" OR "National Hospital Register" OR "Hospital In-Patient
Enquiry" OR "HIPE" OR "Utrecht General Practitioner Research Network" OR "Christelijke Mutualiteiten health insurance" OR "MigMed2" OR
"Hospital Discharge Registers" OR "Ambulatory Care Classification System" OR "ACCS" OR "Physician Claims Database" OR "Medical Services
Plan" OR "Discharge Abstracts Database" OR "Régie de l’Assurance Maladie du Quebec" OR "RAMQ" OR "MED-ECHO" OR "Fichier des
événements démographiques" OR "The Health Improvement Network" OR "Oxford Record Linkage" OR "PharMetrics" OR "National Inpatient
Sample" OR "Mutuelle Générale de l’Education Nationale" OR "INSS Unified Benefit System"
36991
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Search
ID
Query Number of
matching
articles
#3 ("Premier" [All] OR "Solucient" [All] OR "Cerner" [All] OR "Ingenix" [All] OR "LabRx" [All] OR "IHCIS" [All] OR "marketscan" [All] OR "market
scan" [All] OR "Medstat" [All] OR "Thomson" [All] OR "pharmetrics" [All] OR "healthcore" [All] OR "united healthcare" [All] OR "UnitedHealthcare"
[All] OR "UHC" [All] OR "Research Database" [All] OR "Group Health" [All] OR "HCUP" [All] OR ("Healthcare Cost" [All] AND "Utilization Project"
[All]) OR ("Health Care Cost" [All] AND "Utilization Project" [All]) OR "MEPS" [All] OR "Medical Expenditure Panel Survey" [All] OR "NAMCS"
[All] OR "National Hospital Ambulatory Medical Care Survey" [All] OR "National Ambulatory Medical Care Survey" [All] OR "NHIS" [All] OR
"National Health Interview Survey" [All] OR "Kaiser" [All] OR "Kaiser-Permanente" [All] OR "Kaiser Permanente" [All] OR "HMO Research" [All] OR
"Health Maintenance Organization" [All] OR "HMO" [All] OR "Cleveland Clinic" [All] OR "Lovelace" [All] OR "Department of Defense" [All] OR
"Henry Ford" [All] OR "i3 Drug Safety" [All] OR "i3" [All] OR "Aetna" [All] OR "Humana" [All] OR "Wellpoint" [All] OR "IMS" [All] OR
"Intercontinental Marketing Services" [All] OR "IMS Health" [All] OR "Geisinger" [All] OR "GE Healthcare" [All] OR "MQIC" [All] OR "PHARMO"
[All] OR "Institute for Drug Outcome Research" [All] OR "Pilgrim" [All] OR "Puget Sound" [All] OR "Regenstrief" [All] OR "Saskatchewan" [All] OR
"Tayside" [All] OR "MEMO" [All] OR "Veterans Affairs" [All] OR "Partners Healthcare" [All] OR "Mayo Clinic" [All] OR "Rochester Epidemiology"
[All] OR "Indiana Health Information Exchange" [All] OR "Indiana Health" [All] OR "Intermountain" [All] OR "blue cross" [All] OR "health partners"
[All] OR "health plan" [All] OR "health services" [All] OR "Nationwide Inpatient Sample" [All] OR "National Inpatient Sample" [All] OR "medicaid"
[All] OR "medicare" [All] OR "MediPlus" [All] OR "Outcome Assessment" [All] OR (TennCare [tiab]) OR (RAMQ [tiab]) OR (Cigna [tiab]) OR
((british columbia [tiab]) AND ((health [tiab]) OR (data [tiab]) OR (database [tiab]) OR (population [tiab]))) OR (CIHI [All Fields]) OR ((manitoba
[tiab]) AND ((center for health policy [all fields]) OR (population [tiab]) OR (health insurance [tiab]))) OR ((ontario [tiab]) AND ((population [tiab])
OR (OHIP [tiab]) OR (registered persons database [tiab]) OR (health insurance [tiab]) OR (ICES [All Fields]) OR (Institute for Clinical Evaluative
Sciences [All Fields]))) OR ((Alberta [tiab]) AND ((health [tiab]) OR (data [tiab]) OR (database [tiab]) OR (population [tiab]) OR (Alberta Health and
Wellness [All Fields]))) OR "ICD-9-CM" [All Fields] OR "ICD-10-CM" [All Fields] OR "ICD-9" [All] OR "ICD-10" [All] OR "international statistical
classification" [All] OR "international classification of diseases" [All] OR "Database Management Systems" [Mesh] OR "Medical Records Systems,
Computerized" [Mesh] OR "CPT" [All] OR "Current procedural terminology" [All] OR "OPCS4" OR "OPCS-4" OR "Read code*" OR "SNOMED-CT"
OR "J45*" OR "H33*" OR "insurance database" [All] OR "insurance databases" [All] OR "health insurance claim*" OR "health insurance data*" OR
"claim data" OR "claims data" OR ("claims" [tw] AND "administrative" [tw]) OR "Insurance Claim Review"[mh] OR ((medical OR pharmacy) AND
claim) OR ((medical OR pharmacy) AND claims) OR "Insurance Claim Reporting"[mh] OR "routine data" OR "routine health data" OR "routine
clinical data" OR "routine electronic data" OR "routinely collected data" OR "routinely-collected data" OR "routinely-collected health data" OR "drug
surveillance" [All] OR "pharmacy data" OR "dispensing data" OR "administrative data" OR "administrative health data" OR "health administrative
data" OR ("data" [tw] AND "administrative" [tw]) OR "database analysis" OR "register" OR "registry" OR "Databases, Factual" [Mesh] OR
"Databases as topic" [Mesh] OR "Data Warehouse" [All] OR "Medical Record Linkage" [Mesh] OR "record-linkage" OR "record linkage")
996792
#4 #1 AND (#2 OR #3) 307
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Table E2: Charting table including data extracted from the reviewed articles.
Variable Notes
General
Title/Year
Country
Study design
Routine data sources used We extracted the names and types of the
routine datasets from which asthma variables are
measured or derived.
Algorithms and case definitions
Asthma Includes asthma labels, case definitions,
comorbidity and age exclusions, as well as
validity reporting. We distinguished in each
study between the criteria for defining ‘asthma’
and the study-specific criteria for subject
selection which can be more specific.
Asthma severity Also includes validity reporting.
Asthma control Also includes validity reporting.
Asthma exacerbation Also includes validity reporting.
Clarity of reporting routine data-related methods
Title and abstract
RECORD 1.1: Types or names of routine data sources used are mentioned
RECORD 1.2: Geographical regions covered by the routine data sources used are mentioned
RECORD 1.2: Study-time frame is mentioned
RECORD 1.3: Record linkage is mentioned (if used)
Methods
RECORD 6.1: Selection process of study population is mentioned in detail; clinical codes for asthma case
definitions are reported
Clinical codes could be either in the Methods
section or in supplementary documents.
RECORD 6.2: Validation for case definitions
RECORD 6.3 and 12.3: Record-linkage, if used, is sufficiently explained
RECORD 7.1: List of codes used in study variables
RECORD 12.1: Authors explained their level of access to database population
RECORD 12.2: Data cleaning is explained
Results
RECORD 13.1: Details of study population selection
Discussion
18
Variable Notes
RECORD 19.1: Implications of using routine data for asthma research (e.g. misclassification bias,
unmeasured confounding, missing data, and changing eligibility over time)
RECORD 22.1: Information on how to access study protocol, raw data, and programming code is
mentioned
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Table E3: Geographical distribution of the reviewed studies.
Country Number of studies
USA 52
Taiwan 20
Canada 12
Sweden 4
Denmark 4
UK 3
Republic of Korea 2
Israel 2
France 2
Finland 2
Europe 2
USA, UK 1
Spain 1
Singapore 1
Portugal 1
Netherlands 1
Korea 1
Italy 1
Iran 1
Australia 1
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Table E4: Study designs of the reviewed studies.
Study design Number of studies
cohort study, retrospective, using routine database(s) 62
cross-sectional / prevalence study 27
nested case-control 5
cohort study, prospective, using routine database(s) 5
validation study 3
time series analysis 3
population based cross-sectional ecological study 2
cohort study, retrospective, linked to self-reported data 1
cohort study, retrospective, linked to medical charts 1
cohort study, retrospective, linked to death registry 1
case-crossover study 1
case-control study 1
case-control 1
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Table E5: Types of EHR-derived data sources used in the reviewed articles.
Type Number of studies
health insurance claim 72
medical records or medical administrative data 39
dispensing 13
mortality with causes of death 2
public health surveillance database 1
medical birth register 1
health insurance claim + medical records 1
drug adverse effect surveillance 1
disease register 1
22
Table E6: Algorithms used to identify asthma patients.
Label Algorithm Number of
studies
asthma asthma encounter (position = unspecified) ≥ 1 22
IP (position = unspecified) ≥ 1 7
Rx ≥ 1 5
IP (position = unspecified) ≥ 1 OR OP (position = unspecified) ≥ 1 OR ED (position = unspecified) ≥ 1 3
asthma encounter (position = 1) ≥ 1 3
IP (position = unspecified) ≥ 1 OR OP (position = unspecified) ≥ 2 2
IP (position = unspecified) ≥ 1 OR OP (position = unspecified) ≥ 2 2
IP (position = unspecified) ≥ 1 OR OP (position = unspecified) ≥ 1 2
IP (position = 1) ≥ 1 2
ED (position ≤ 3) ≥ 1 2
asthma encounter (position = unspecified) ≥ 1 OR Rx ≥ 1 2
asthma encounter (position = unspecified) ≥ 1 AND Rx ≥ 2 within 12 months 2
SABA ≥ 1 AND (ICS, inhaled anticholinergics, Theo, LTRA, OCS, Combo) ≥ 2 OR LABA-ICS ≥1 1
Rx ≥ 1 within 12 months 1
Rx > 1 OR omalizumab ≥ 1 within 12 months 1
OP (position = unspecified) ≥ 3 OR IP (position = unspecified) ≥ 1 1
OP (position = unspecified) ≥ 2 OR IP (position = unspecified) ≥ 2 1
OP (position = unspecified) ≥ 2 OR IP (position = 1) ≥ 1 within 12 months 1
OP (position ≤ 2) ≥ 2 OR IP (position = unspecified) ≥ 1 OR ED (position = unspecified) ≥ 1 1
OP (position ≤ 2) ≥ 2 OR ED (position = 1) ≥ 1 OR IP (position = 1) ≥ 1 1
IP OR ED (position = 1 or second to a repiratory diagnosis) ≥ 1 1
IP (position ≥ 1) ≥ 1 OR OP (position ≥ 1) ≥ 2 within 2 years 1
IP (position ≥ 1) ≥ 1 OR OP (position ≥ 1) ≥ 2 1
IP (position ≥ 1) ≥ 1 OR OP (position ≥ 1) ≥ 1 1
IP (position = unspecified) ≥ 1 OR OP (position = unspecified) ≥ 3 within 36 months 1
IP (position = unspecified) ≥ 1 OR OP (position = unspecified) ≥ 2 within 12 months 1
IP (position = unspecified) ≥ 1 OR OP (position = unspecified) ≥ 2 OR ED (position = unspecified) ≥ 2 OR within 24 months 1
IP (position = unspecified) ≥ 1 OR OP (position = unspecified) ≥ 1 OR ED (position = unspecified) ≥ 1 1
IP (position = unspecified) ≥ 1 OR OP (position = unspecified) ≥ 1 within 1 year 1
IP (position = unspecified) ≥ 1 OR OP (position = unspecified) ≥ 1 OR Rx ≥ 4 within 12 months 1
IP (position = unspecified) ≥ 1 OR (OP (position = unspecified) + ED (position = unspecified)) ≥ 2 1
ED = emergency department visit ; GP = general practitioner visit ; ICS = inhaled corticosteriod ; IP = inpatient hospitalisation ; LABA = long-acting beta agonist ; LTRA =
leukotriene receptor antagonist ; OCS = oral corticosteroids ; OP = outpatient visit ; RSV = respiratory syncytial virus ; SABA = short-acting beta2-agonists
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Table E6: Algorithms used to identify asthma patients.(cont’d)
Label Algorithm Number of
studies
IP (position = unspecified) ≥ 1 AND Rx ≥ 1 1
IP (position = 1) OR OP (position = 1) ever 1
IP (position = 1) ≥ 1 OR IP (position = 2 or 3, following pneumonia/influenza, respiratory failure, RSV/bronchiolitis) 1
IP (position ≤ 2) ≥ 1 1
GP (position ≤ 2) ≥ 1 OR IP (position ≤ 2) ≥ 1 OR ED (position ≤ 2) ≥ 1 OR asthma urgent care visit (position ≤ 2) ≥ 1 OR Rx
≥ 1
1
ED (position = any) ≥ 1 OR wheeze ≥ 1 1
ED (position = 1) ≥ 1 1
ED (position = 1 to 11) ≥ 1 1
based on ICS 1
based on asthma medications 1
asthma encounter (position = unspecified) ≥ 2 within 12 months 1
asthma encounter (position = unspecified) ≥ 2 ever 1
asthma encounter (position = unspecified) ≥ 2 1
asthma encounter (position = unspecified) ≥ 1 within 12 months 1
asthma encounter (position = unspecified) ≥ 1 OR Rx within 6 months 1
asthma encounter (position = unspecified) ≥ 1 OR Rx ≥ 2 ever 1
asthma encounter (position = unspecified) ≥ 1 OR Rx ≥ 1 ever 1
asthma encounter (position = unspecified) ≥ 1 OR ICS ≥ 1 within 12 months 1
asthma encounter (position = unspecified) ≥ 1 OR asthma medications ≥2 1
asthma encounter (position = unspecified) ≥ 1 ever 1
asthma encounter (position = unspecified) ≥ 1 AND Rx ≥ 2 within 24 months 1
asthma encounter (position = unspecified) ≥ 1 AND Rx ≥ 2 1
asthma encounter (position = unspecified) ≥ 1 AND Rx ≥ 1 within 12 months 1
asthma encounter (position = unspecified) ≥ 1 AND Rx ≥ 1 1
asthma encounter (position = unspecified) ≥ 1 AND current Rx ≥ 2 1
asthma encounter (position = unspecified) ≥ 1 AND current Rx ≥ 1 1
asthma encounter (position = unspecified) ≥ 1 AND Rx ≥ 2 1
asthma encounter (position = unspecified) ≥ 1 AND Rx ≥ 1 1
(asthma encounter (position = 1) ≥ 1 OR asthma encounter (position ≥ 1) ≥ 4) AND (asthma prescriptions ≥1 OR asthma tests
≥ 1) within 5 years
1
current asthma asthma encounter (position = unspecified) ≥ 1 1
ED = emergency department visit ; GP = general practitioner visit ; ICS = inhaled corticosteriod ; IP = inpatient hospitalisation ; LABA = long-acting beta agonist ; LTRA =
leukotriene receptor antagonist ; OCS = oral corticosteroids ; OP = outpatient visit ; RSV = respiratory syncytial virus ; SABA = short-acting beta2-agonists
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Table E6: Algorithms used to identify asthma patients.(cont’d)
Label Algorithm Number of
studies
current GP-reported
asthma
asthma encounter (position = unspecified) ≥ 1 within 12 months 1
current treated asthma asthma encounter (position = unspecified) ≥ 1 AND Rx ≥ 1 within 12 months 1
treated asthma Rx > = 3 within 12 months 1
persistent asthma Rx ≥ 4 OR IP ≥ 1 OR ED (position = 1) ≥ 1 OR (OP (position = any) ≥ 1 AND Rx ≥ 2) within 12 months 2
Rx ≥ 4 OR IP ≥ 1 OR ED (position = 1) ≥ 1 OR (OP (position = any) ≥ 1 AND Rx ≥ 2) within 24 months 1
Rx ≥ 4 OR IP ≥ 1 OR ED (position = 1) ≥ 1 OR (OP (position = any) ≥ 1 AND Rx ≥ 2) within 12 months 1
Rx ≥ 4 OR IP ≥ 1 OR ED (position = 1) ≥ 1 OR (OP (position = any) ≥ 1 AND Rx ≥ 2) 1
IP (position = unspecified) ≥ 1 OR ED (position = unspecified) ≥ 1 OR OCS ≥ 3) within 12 months 1
ED = emergency department visit ; GP = general practitioner visit ; ICS = inhaled corticosteriod ; IP = inpatient hospitalisation ; LABA = long-acting beta agonist ; LTRA =
leukotriene receptor antagonist ; OCS = oral corticosteroids ; OP = outpatient visit ; RSV = respiratory syncytial virus ; SABA = short-acting beta2-agonists
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Table E7: Approaches used in identifying asthma patients.
Criteria base on Diagnostic label used Number of studies
Asthma diagnostic/management codes
‘asthma’ 68
persistent asthma 1
acute asthma 1
current asthma 1
current GP-reported and
diagnosed asthma
1
Asthma diagnostic/management codes
AND asthma prescription codes
‘asthma’ 11
current treated asthma 1
persistent asthma 2
Asthma prescription codes
asthma 22
treated asthma 1
persistent asthma 4
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Table E8: Approaches used in identifying asthma patients.
Age limits Studies Number of studies
Minimum age limits
6 months E2 1
2 years E3–E8 6
3 years E9–E11 3
5 years E12–E14 3
Maximum age limits
44 years E15 1
55 years E16 1
60 years E17 1
64 years E18 1
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Table E9: Co-morbidities and conditions based on which asthma patients were excluded.
Condition Number of studies
COPD 11
Cystic fibrosis 13
Pulmonary embolism 3
Bronchiectasis 4
Pulmonary hypertension 4
Congestive heart failure 3
Emphysema 3
Chronic bronchitis 2
Immunodeficiency 2
Churg Strauss syndrome 1
Wegener syndrome 1
Sarcoidosis 1
Smoker over age of 60 1
Pneumonia 1
Anti-cholinergic prescription as a proxy of COPD 1
Chronic respiratory failure 1
Achondroplasia 1
Bronchopulmonary dysplasia 1
Respiratory cancer 1
Active or past tobacco use 1
Primary ciliary dyskinesia 1
Tracheomalacia 1
Bronchiolitis/RSV infection 2
Pneumoconiosis 1
Other lung diseases due to external agents 1
Psychosis 1
“Perinatal respiratory condition” 1
Tracheostomy 1
Gastrostomy 1
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Table E10: Algorithms used to ascertain asthma severity using EHR data.
Variable Algorithm Interval
(months)
Appears in Validated by
Mild asthma either
500 mg/day of ICS monotherapy (in beclomethasone
chlorofluorocarbon equivalents)
OR
250 mg/day of ICS + additional controller
AND
either
≤ 3 SABA doses per week on average (each = 2
salbutamol 100mg puffs)
OR
both
4−10 doses of SABA per week on average
AND
no moderate to severe asthma exacerbation (defined
as asthma ED visit OR asthma hospitalization OR
short−course OCS)
12 [E19] previous study(-ies) on same
database(s)
Moderate asthma NOT mild asthma NOR severe asthma as defined in the same
study
12 [E19] previous study(-ies) on same
database(s)
Severe asthma > 1000 mg/day of ICS
AND
one of
> 3 SABA per week on average
OR
≥ 1 moderate to severe asthma exacerbation
OR
both
lower doses of ICS with >10 SABA doses per week on
average
AND
1 moderate to severe asthma exacerbation
12 [E19] previous study(-ies) on same
database(s)
> 6 albuterol refills per year 12 [E3] not justified
GINA step 4 or higher unclear [E20] Based on GINA guidelines
continuous treatment with ICS (at least 800 mg budesonide
daily or equivalent [500 mg fluticasone]) and (LABA)
12 [E21] not justified
presence of persistent asthma according to the HEDIS criteria
associated with readmission
OR
presence of complex chronic condition within the prior year
associated with readmission
12 [E5] previous study(-ies) on different
database(s)
based on number of ICS, LABA, and OCS prescriptions 24 [E22] not justified
based on number of asthma prescriptions (including OCS) 12 [E23] not justified
ED = emergency department; GINA = Global Initiative for Asthma; HEDIS = Healthcare Effectiveness Data and Information Set; ICS = inhaled corticosteroids; LABA =
long-acting β2 agonists; OCS = oral corticosteroids; OP = outpatient; SABA = short-acting β2 agonists
.
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Table E10: Algorithms used to ascertain asthma severity using EHR data.(cont’d)
Variable Algorithm Interval
(months)
Appears in Validated by
based on asthma hospitalisation, asthma Ed visits, outpatient
visits for asthma exacerbation, number of SABA dispensings,
number of OCS dispensings
12 [E24] previous study(-ies) on different
database(s)
based on number of of asthma hospitalisations, asthma ED
visits, SABA prescriptions, OCS prescriptions, and asthma
exacerbations over 6 months
6 [E14] previous study(-ies) on different
database(s)
based on acute OCS course, mean daily SABA dose, number
of asthma consultations with no acute OCS
12 [E17] not justified
ICS (>800 mg
budesonide daily) AND second controller
OR
ICS−LABA
OR
omalizumab
12 [E15] Based on clinical guidelines
According to GINA 2006 classification of severity unclear [E25] Based on clinical guidelines
Based on OCS prescriptions unclear [E26] not justified
Number of OP over variable follow−up periods variable [E27] not justified
‘More severe asthma’ ≥ 2 SABA prescriptions within 90 days of ICS prescriptions 3 [E28] previous study(-ies) on different
database(s)
HEDIS criteria for persistent asthma:
≥ 1 asthma hospitalisation
OR
≥ 1 asthma ED visit
OR
≥ 4 asthma prescriptions
OR
both
≥ 4 asthma outpatient visits
AND
≥ 2 asthma prescriptions
24 [E7] previous study(-ies) on different
database(s)
≥ 1 asthma hospitalisations or ED visits 12 [E29] not justified
Low-risk asthma no asthma ED visits
AND
no asthma hospitalisations
AND
< 15 β−agonist canisters dispensed
AND
no OCS dispensed
12 [E10] previous study(-ies) on different
database(s)
ED = emergency department; GINA = Global Initiative for Asthma; HEDIS = Healthcare Effectiveness Data and Information Set; ICS = inhaled corticosteroids; LABA =
long-acting β2 agonists; OCS = oral corticosteroids; OP = outpatient; SABA = short-acting β2 agonists
.
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Table E10: Algorithms used to ascertain asthma severity using EHR data.(cont’d)
Variable Algorithm Interval
(months)
Appears in Validated by
Moderate-risk
asthma
no asthma ED visits
AND
no asthma hospitalisations
AND
only one of:
≥ 15 β−agonist canisters dispensed
OR
≥ 1 OCS dispensings
12 [E10] previous study(-ies) on different
database(s)
High-risk asthma ≥ 1 asthma ED visits
OR
≥ 1 asthma hospitalisations
OR
both:
≥ 15 β−agonist canisters dispensed
AND
≥ 1 OCS dispensings
12 [E10] previous study(-ies) on different
database(s)
ED = emergency department; GINA = Global Initiative for Asthma; HEDIS = Healthcare Effectiveness Data and Information Set; ICS = inhaled corticosteroids; LABA =
long-acting β2 agonists; OCS = oral corticosteroids; OP = outpatient; SABA = short-acting β2 agonists
.
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Table E11: Algorithms used to ascertain asthma exacerbation using EHR data.
Variable Study Algorithm OCS IP ED OP GP SABA Validity
reporting
alone + OP + IP,
ED, OP
or GP
+ IP
or ED
Exacerbation [E30] ≥ 1 OCS prescription for < 21 days
OR
≥ 4 asthma GP visits per year
OR
≥ 5 SABA prescriptions per year
< 21
days
≥
4/yr
> 5/yr based on
a
national
expert
review
[E31]
[E15] ≥ 1 OCS prescription
OR
Hospitalisation or ED visit for asthma,
status asthmaticus, pneumonia,
dyspnoea, or respiratory insufficiency
≥ 1 p p previous
study(-
ies) on
different
database(s)
[E32] asthma hospitalisation
OR
asthma ED visit
OR
OCS pharmacy claim
p p p not
justified
[E20] OCS prescription within 7 days of any
asthma encounter (which may
include hospitalisation, ED,
outpatient, or GP visit, ascertained
with the ICD−9 code 493 as a
primary diagnosis or as a secondary
diagnosis provided the primary
diagnosis is another respiratory
condition)
Variation: asthma encounter = asthma
hospitalisation or ED visit only
within 7
days
within
7 days
not
justified
[E22] OCS with asthma as indication
OR
asthma ED visit
OR
asthma hospitalisation
indication
is
asthma
p p not
justified
p = present; a = absent; OCS = oral corticosteroids; AE = asthma exacerbation; SABA = short-acting β2 agonists; ED = emergency department; ICD = International Classification
of Diseases; IP = inpatient hospitalisation; OP = outpatient; GP = general practitioner.
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Table E11: Algorithms used to ascertain asthma exacerbation using EHR data. (cont’d)
Variable Study Algorithm OCS IP ED OP GP SABA Validity
reporting
alone + OP + IP,
ED, OP
or GP
+ IP
or ED
[E23] OCS prescription
OR
number of asthma GP visits
OR
hospitalisation for asthma (as a
primary diagnosis; variation: as a
priamry or secondary diagnosis)
p p p not
justified
[E33] Occurrence, after 3 months from
previous asthma hospitalisation, if
any, of:
OCS short−course
OR
asthma ED visit (ICD−9−CM =
493)
OR
asthma hospitalisation
(ICD−9−CM = 493)
p p p not
justified
[E34] Primary hospital discharge diagnosis of
asthma exacerbation
p not
justified
[E35] ED visit with primary diagnosis of
asthma
OR
outpatient visit with
diagnosis of asthma exacerbation
OR
diagnosis of asthma with OCS
prescription (< 14−day supply)
within 5 days
OR
hospitalization with diagnosis of
asthma (primary) or asthma
exacerbation (any position)
<
14-day
supply;
within
5 days
p p Dx is
AE
not
justified
[E36] OCS use
OR
asthma ED visit
OR
asthma hospitalisation
p p p not
justified
p = present; a = absent; OCS = oral corticosteroids; AE = asthma exacerbation; SABA = short-acting β2 agonists; ED = emergency department; ICD = International Classification
of Diseases; IP = inpatient hospitalisation; OP = outpatient; GP = general practitioner.
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Table E11: Algorithms used to ascertain asthma exacerbation using EHR data. (cont’d)
Variable Study Algorithm OCS IP ED OP GP SABA Validity
reporting
alone + OP + IP,
ED, OP
or GP
+ IP
or ED
[E24] outpatient visit with primary diagnosis
of asthma (ICD−9−CM = 493) and
OCS dispensing within 5 days
OR
asthma ED visit (ICD−9−CM =
493.xx)
OR
asthma hospitalization (ICD−9−CM =
493.xx)
within
5 days
p p not
justified
[E37] ED visit with any asthma diagnosis
OR
hospitalization with primary diagnosis
asthma
OR
OCS with asthma claim within 7 days
within 7
days
p p not
justified
[E38] one−off OCS prescription
(short−course) p notjustified
[E39] OCS within 7 days of an encounter
with diagnosis of exacerbation or
uncontrolled asthma
P
[E40] ≥ 1 asthma ED visits
OR
≥ 1 asthma hospitalizations
OR
OCS prescriptions
p p p not
justified
[E41] asthma ED visit (ICD−9−CM = 493)
AND/OR
asthma hospitalisation (ICD−9−CM =
493)
p p not
justified
[E9] Encounter with asthma exacerbation
code
not
justified
p = present; a = absent; OCS = oral corticosteroids; AE = asthma exacerbation; SABA = short-acting β2 agonists; ED = emergency department; ICD = International Classification
of Diseases; IP = inpatient hospitalisation; OP = outpatient; GP = general practitioner.
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Table E11: Algorithms used to ascertain asthma exacerbation using EHR data. (cont’d)
Variable Study Algorithm OCS IP ED OP GP SABA Validity
reporting
alone + OP + IP,
ED, OP
or GP
+ IP
or ED
[E17] acute OCS
OR
unscheduled asthma hospitalisation
OR
ED visit
p p p not
justified
[E18] new occurrence (after >= 8−day
wash−up period) of:
Both
Asthma outpatient visit (with
a code for acute
exacerbation, status
asthmaticus, acute asthma
attack, uncontrolled asthma,
asthmatic bronchitis)
AND
OCS dispensing within 7 days
OR
Asthma ED visit or hospitalization
(asthma diagnosis position = 1
OR position = 2 following a
primary respiratory diagnosis)
p p p being
based
on na-
tionally
devel-
oped
algo-
rithm(s)
[E42] Asthma hospitalization
OR
Asthma ED visit
OR
Asthma OP visit with OCS prescription
p p p not
justified
[E25] Based on rescue medications not
justified
Moderate-to-
severe
exacerba-
tion
[E19] OCS short−course
OR
asthma ED visit
OR
asthma hospitalisation
p p p previous
study(-
ies) on
same
database(s)
[E14] OCS within 7 days of asthma
outpatient visit
OR
Asthma ED visit
within
7 days
p not
justified
p = present; a = absent; OCS = oral corticosteroids; AE = asthma exacerbation; SABA = short-acting β2 agonists; ED = emergency department; ICD = International Classification
of Diseases; IP = inpatient hospitalisation; OP = outpatient; GP = general practitioner.
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Table E11: Algorithms used to ascertain asthma exacerbation using EHR data. (cont’d)
Variable Study Algorithm OCS IP ED OP GP SABA Validity
reporting
alone + OP + IP,
ED, OP
or GP
+ IP
or ED
Moderate ex-
acerbation
[E43] ≥ 1 ED visits for asthma
AND
no hospitalisation for asthma
a p being
consis-
tent
with
algo-
rithms
used in
previous
similar
studies
on
different
database(s)
Severe exac-
erbation
[E43] ≥ 1 hospitalisation for asthma as a
primary or admission diagnosis
p being
consis-
tent
with
algo-
rithms
used in
previous
similar
studies
on
different
database(s)
p = present; a = absent; OCS = oral corticosteroids; AE = asthma exacerbation; SABA = short-acting β2 agonists; ED = emergency department; ICD = International Classification
of Diseases; IP = inpatient hospitalisation; OP = outpatient; GP = general practitioner.
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Table E12: Algorithms used to assess asthma control using EHR data
Variable Algorithm Interval Appears in Validated by
Low control/
uncontrolled asthma
≥ 600 doses (1 dose = 1 puff) of SABA in the recent year
OR
≥ 1 exacerbation in the recent year, defined as:
≥ 1 hospitalisation or ED visit associated with ICD−10 code for asthma,
status asthmaticus, pneumonia, dyspnoea, or respiratory insufficiency
OR
≥ 1 OCS prescription
12 months [E15] previous study(-ies)
on different
database(s)
≥ 1 hospitalisation or ED visit
OR
dispensing of OCS for ≥ 3 days
12 months [E40] not justified
≥ 1 ED or OP visit for asthma
OR
≥ 1 antibiotic prescriptions
unclear [E44] previous study(-ies)
on same
database(s)
≥ 1 moderate to severe asthma exacerbation
AND
> 3 and 10 SABA doses per week on average for mild and moderate/severe
asthma, respectively
12 months [E19] previous study(-ies)
on same
database(s)
≥ 2 acute care contact within 1 month
OR
≥ 3 reliever inhaler uses per week
OR
severe exacerbation requiring ICU/intubation in the last 3 months
OR
asthma hospitalisation in the last 3 months
1-3 months [E25] previous study(-ies)
on same
database(s)
at the assessment date
> 2 asthma drug classes
OR
≥ 1 SABA
OR
in 12 months
≥ 1 OCS
OR
≥ 6 SABA
OR
≥ 1 asthma ED visits
OR
≥ 1 asthma hospitalisations
12 months [E38] being consistent
with algorithms
used in previous
similar studies on
the same
database
LRTI = lower respiratory tract infection; SABA = short-acting β agonists; OCS = oral corticosteroids; GP = general practitioner; ED = emergency department; ICD =
International Classification of Diseases
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Table E12: Algorithms used to assess asthma control using EHR data (cont’d)
Variable Algorithm Interval Appears in Validated by
Low-risk asthma control Absence of all the following:
hospitalisation, ED, and unscheduled outpatient visits for asthma
(ascertained by any asthma or LRTI codes)
GP consultation for LRTI requiring antibiotics
acute course of OCS
12 months [E17] previous study(-ies)
on different
database(s)
based on number of OCS prescriptions per year 12 months [E45] previous study(-ies)
on different
database(s)
Impairment-domain
asthma control
based on number of β−agonists prescriptions per year 12 months [E45] previous study(-ies)
on different
database(s)
> 2 salbutamol puffs per day (> 200µg in the UK and > 180µg in the US) 12 months [E17] previous study(-ies)
on different
database(s)
Overall asthma control based on impairment−domain and risk−domain asthma control algorithms
used by the same study
12 months [E17] previous study(-ies)
on different
database(s)
LRTI = lower respiratory tract infection; SABA = short-acting β agonists; OCS = oral corticosteroids; GP = general practitioner; ED = emergency department; ICD =
International Classification of Diseases
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